Peter Marks is an American hematologist oncologist serving as the director of the Center for Biologics Evaluation and Research within the Food and Drug Administration.

[3][4] In May 2020, he was selected to serve as a member of the White House Coronavirus Task Force,[5] although he left a few days later over concerns that his participation would represent a conflict with his position at FDA.

[6] Marks also played a role in establishing Operation Warp Speed, a partnership between the federal government and various private companies to develop a COVID-19 vaccine, but left the project in May 2020 shortly after it was launched.

Marks believed he would be more useful in his role as chief regulator of vaccines as the Director of FDA's Center for Biologics Evaluation and Research.

[10] In 2024, Marks overruled FDA staff to approve gene pharmacotherapy Elevidys—intended to treat Duchenne muscular dystrophy—despite it failing in Phase III clinical trial.